This document was written to highlight available literature, orientate and provide context for the senate panel on the areas below for the South East Clinical Best Practice Review of Clinical Pathways Identified as Areas of Uncertainty and Differing Opinion – August 2025.
- Direct oral anticoagulant (DOAC) management
- Disease modifying anti-rheumatic drug (DMARD) monitoring
- Monoclonal gammopathy of undetermined significance (MGUS) follow up and monitoring
- Prostate specific antigen (PSA) monitoring
- Post-bariatric surgery monitoring and management
- Monitoring of eating disorders
- Insertion and management of ring pessaries